These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 28261749)
1. Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT. Sandberg D; Tolmachev V; Velikyan I; Olofsson H; Wennborg A; Feldwisch J; Carlsson J; Lindman H; Sörensen J Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1337-1346. PubMed ID: 28261749 [TBL] [Abstract][Full Text] [Related]
2. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT. Sörensen J; Velikyan I; Sandberg D; Wennborg A; Feldwisch J; Tolmachev V; Orlova A; Sandström M; Lubberink M; Olofsson H; Carlsson J; Lindman H Theranostics; 2016; 6(2):262-71. PubMed ID: 26877784 [TBL] [Abstract][Full Text] [Related]
3. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. Sörensen J; Sandberg D; Sandström M; Wennborg A; Feldwisch J; Tolmachev V; Åström G; Lubberink M; Garske-Román U; Carlsson J; Lindman H J Nucl Med; 2014 May; 55(5):730-5. PubMed ID: 24665085 [TBL] [Abstract][Full Text] [Related]
4. Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients. Sandström M; Lindskog K; Velikyan I; Wennborg A; Feldwisch J; Sandberg D; Tolmachev V; Orlova A; Sörensen J; Carlsson J; Lindman H; Lubberink M J Nucl Med; 2016 Jun; 57(6):867-71. PubMed ID: 26912439 [TBL] [Abstract][Full Text] [Related]
5. Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [ Altena R; Burén SA; Blomgren A; Karlsson E; Tzortzakakis A; Brun N; Moein MM; Jussing E; Frejd FY; Bergh J; Tran TA; Hartman J; Axelsson R J Nucl Med; 2024 May; 65(5):700-707. PubMed ID: 38548353 [TBL] [Abstract][Full Text] [Related]
7. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. Ahlgren S; Orlova A; Wållberg H; Hansson M; Sandström M; Lewsley R; Wennborg A; Abrahmsén L; Tolmachev V; Feldwisch J J Nucl Med; 2010 Jul; 51(7):1131-8. PubMed ID: 20554729 [TBL] [Abstract][Full Text] [Related]
8. Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer. Alhuseinalkhudhur A; Lubberink M; Lindman H; Tolmachev V; Frejd FY; Feldwisch J; Velikyan I; Sörensen J EJNMMI Res; 2020 Mar; 10(1):21. PubMed ID: 32201920 [TBL] [Abstract][Full Text] [Related]
9. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma. Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837 [TBL] [Abstract][Full Text] [Related]
10. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. Baum RP; Prasad V; Müller D; Schuchardt C; Orlova A; Wennborg A; Tolmachev V; Feldwisch J J Nucl Med; 2010 Jun; 51(6):892-7. PubMed ID: 20484419 [TBL] [Abstract][Full Text] [Related]
11. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. Ulaner GA; Hyman DM; Lyashchenko SK; Lewis JS; Carrasquillo JA Clin Nucl Med; 2017 Dec; 42(12):912-917. PubMed ID: 28872549 [TBL] [Abstract][Full Text] [Related]
12. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. Ulaner GA; Hyman DM; Ross DS; Corben A; Chandarlapaty S; Goldfarb S; McArthur H; Erinjeri JP; Solomon SB; Kolb H; Lyashchenko SK; Lewis JS; Carrasquillo JA J Nucl Med; 2016 Oct; 57(10):1523-1528. PubMed ID: 27151988 [TBL] [Abstract][Full Text] [Related]
13. Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837 [TBL] [Abstract][Full Text] [Related]
14. Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer Shi J; Du S; Wang R; Gao H; Luo Q; Hou G; Zhou Y; Zhu Z; Wang F J Transl Med; 2023 Jan; 21(1):19. PubMed ID: 36631812 [TBL] [Abstract][Full Text] [Related]
15. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody. Malmberg J; Sandström M; Wester K; Tolmachev V; Orlova A Nucl Med Biol; 2011 Nov; 38(8):1093-102. PubMed ID: 22137850 [TBL] [Abstract][Full Text] [Related]
16. Phase I clinical evaluation of Bragina O; Chernov V; Larkina M; Rybina A; Zelchan R; Garbukov E; Oroujeni M; Loftenius A; Orlova A; Sörensen J; Frejd FY; Tolmachev V Theranostics; 2023; 13(14):4858-4871. PubMed ID: 37771776 [TBL] [Abstract][Full Text] [Related]
17. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET. Kramer-Marek G; Shenoy N; Seidel J; Griffiths GL; Choyke P; Capala J Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1967-76. PubMed ID: 21748382 [TBL] [Abstract][Full Text] [Related]
18. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842 [TBL] [Abstract][Full Text] [Related]